Abstract
In this present work, to synthesis alkyl and aryl substituted monocationic ionic liquids (ILs) of 1–benzyl–3–octadecylimidazolium bromide (ILa), 1–benzyl–3–octadecylbenzimidazolium bromide (ILb), 1–benzyl–3–ethylbenzimidazolium bromide (ILc), 1–benzyl–3–ethylimidazolium bromide (ILd) and 1–benzylpyridinium bromide (ILe), the synthesized ILs are structurally characterized using various physico–chemical, analytical and spectral (FT–IR, 1H & 13C NMR, EI-MS) studies. The synthesized ILs of 1–benzyl–3–ethylbenzimidazolium bromide (ILc), 1–benzyl–3–ethylimidazolium bromide (ILd) and 1–benzylpyridinium bromide (ILe) exhibited significant in vitro biological and antioxidant activities. Furthermore, the synthesized ILs (ILa– ILe) were tested for their in vitro cytotoxicity against human leukemia cancer cell line K–562, human ovarian cancer cell line SK–OV–3, human prostate cancer cell line DU–145 and human non-tumor cell line (normal fetal lung fibroblasts, MRC-5) by SRB assay protocol. The results indicate that 1–benzyl–3–octadecylimidazolium bromide (ILa) and 1–benzyl–3–octadecylbenzimidazolium bromide (ILb) showed remarkable toxicity against cancer cells and low toxicity against healthy cell line. These facts open the possibility of designing new nontoxic ionic liquids that can be used as active pharmaceutical ingredients in the liquid form.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
